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a b s t r a c t
A recombinant Salmonella enterica serovar Typhimurium (S. Typhimurium) vaccine strain was con-
structed that stably expressed the Mycobacterium tuberculosis fusion antigen Ag85B–ESAT6 from the
chromosome. Live oral vaccination of mice with the Salmonella/Ag85B–ESAT6 strain generated a potent
anti-Ag85B–ESAT6 TH1 response with high antibody titres with a IgG2a-bias and signiﬁcant IFN- pro-
duction lasting over a 120-day period. When mice primed with the Salmonella/Ag85B–ESAT6 vaccine
were mucosally boosted with the Ag85B–ESAT6 antigen and adjuvant the IFN- responses increased
markedly. To determine the protective efﬁcacy of this vaccine strain, guinea pigs were immunised
and followed for a 30-week period after aerosol challenge with M. tuberculosis. The heterologous
prime-boost strategy of live Salmonella vaccine followed by a systemic boost of antigen and adju-
vant reduced the levels of M. tuberculosis bacteria in the lungs and spleen to the same extent as BCG.
Additionally, this vaccination regimen was observed to be statistically equivalent in terms of protec-
tion to immunisation with BCG. Thus, live oral priming with the recombinant Salmonella/Ag85B–ESAT6
and boosting with Ag85B–ESAT6 plus the adjuvant LTK63 represents an effective mucosal vaccination
regimen.. Introduction
Currently, nearly two billion people are infected with Mycobac-
erium tuberculosis. Annually, nine million people become ill with
. tuberculosis-associated tuberculosis and approximately two
illiondie fromthediseaseworldwide,mostly indeveloping coun-
ries. Tuberculosis is also a leading cause of death among Human
mmunodeﬁciency Virus (HIV) infected people, with co-infection
ccounting for up to a third of deaths associated with Acquired
mmunodeﬁciency Syndrome (AIDS), worldwide [1]. Along with
IV/AIDS and malaria, tuberculosis remains as one of the three
ain killers among global infectious diseases [2]. Currently the
nly licensed vaccine in the ﬁght against tuberculosis is Bacille
almette-Guérin (BCG). This live attenuated vaccine has been in
se for over 80 years and has displayed up to 80% efﬁcacy against
erious forms of the disease, e.g., meningitis, in children. However,
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efﬁcacy in adults against pulmonary tuberculosis ranges from 0 to
80% in different trials [3].
M. tuberculosis is a pathogen which normally infects individuals
via the mucosal tissue of the respiratory tract following inhalation
of infectious droplets. Many new tuberculosis vaccination strate-
gies have concentrated on the parenteral route of administration,
which is also how the current live BCG vaccine is delivered in most
parts of the world. However, a number of studies have shown that
delivery via mucosal routes may elicit a local respiratory mucosal
immunity which may increase protection against M. tuberculosis
infection [4–7]. Different strategies can be used to deliver vaccine
antigens via the mucosal route, with living attenuated bacterial
vaccines being among the most promising candidates. The attenu-
ated bacterial antigen vectors can be used to induce immunity to
their corresponding pathogenic strain or they can be modiﬁed to
deliver protective heterologous (foreign) antigens, plasmid DNA or
Open access under CC BY license.othermacromolecules such as immunemodulators [8]. Attenuated
derivatives of Salmonella enterica have been proposed as vehicles
for the mucosal delivery of heterologous antigens and as a basis for
multivalent vaccines. In fact, strains of S. Typhi and S. Typhimurium
were among the ﬁrst bacterial recombinant vaccine vectors used
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Table 1
Details of primers used in study.
Target DNA Primer name Primer sequence (5′–3′)
lacZ-Ag85B-EAT6 from p2795 (primers designed to
include phoN knock-in regions [Hensel Vector])
phoNhensF GCTGTGGCCAGTTTGCGGGAAGACTTTCACCTTCAGTAATTAAGATACGACTCACTCACTATAGGGCG
phoNhensR CTGTTTATTATTGCCTGATCCGGAGTGAGTCTTTATGAAAAGTTGACCATGATTACGCCAAGC
GGAC
CATGA
TTCGC
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1lacZ-Ag85B–ESAT6 (sequencing primers for
chromosomal phoN lacZ-Ag85B–ESAT6 insert)
phoNseqF GGTAT
phoNseqR GAATT
mycoseqR CGTGT
o deliver heterologous antigens [9,10]. Oral vaccination with live
ttenuated Salmonella vectors can result in the generation of both
almonella and heterologous antigen speciﬁc humoral and cellular
mmune responses, normally biased towards TH1 [11,12]. Consid-
rable progress has been made in clinical studies with attenuated
. Typhi-based vaccines, which can be used both as amore effective
yphoid vaccine and for delivery of heterologous antigens [13–15].
ince humans are the only known natural host for S. Typhi, many
trategies for producing attenuated vaccine vectors are initially
ssessed using S. Typhimurium [16–20].
Two of the major antigens produced by M. tuberculosis during
nfections are antigen 85B (Ag85B), a 31kDa mycolyl transferase
nvolved in cellwall biogenesis, and early secreted antigenic target-
(ESAT6), a small 6 kDa protein possibly involved in immune
odulation [21–24]. Ag85B and ESAT6 are both capable of induc-
ng strong immune responses in a number of animal models
25–28]. Previous work has shown that the fusion of Ag85B–ESAT6
s more immunogenic, and gives higher levels of protection com-
ared to the individual antigens when administered parenterally
29–32]. In addition, intranasal (i.n.) immunisation regimens with
g85B–ESAT6, both with the mutant heat labile toxin (LT) adju-
ant LTK63 or a derivative of cholera toxin CTA1-DD/ISCOMs,
ave shown promise [33,34]. Both studies demonstrated potent
nti-Ag85B–ESAT6 immune responses, in addition to signiﬁcant
rotection after M. tuberculosis challenge in a murine model [4,5].
n this present study we evaluated the immunogenicity and pro-
ective efﬁcacy of a novel recombinant S. Typhimurium vaccine
xpressing the Ag85B–ESAT6 fusion antigen as part of a mucosal
rime/boosting vaccination regimen with Ag85B–ESAT6 protein
nd LTK63 adjuvant.
. Materials and methods
.1. Bacterial strains, primers and plasmids
S. Typhimurium SL3261, which harbours an attenuating muta-
ion in the aroA gene, was used as the base vector for all live
accine studies [35] and was routinely grown in (Luria–Bertani)
B-broth supplemented with l-phenylalanine, l-tryptophan, l-
yrosine (40g/mL each) along with p-aminobenzoic acid and
,3-dihydroxybenzoic acid (10g/mL).
For the isolation of the expression cassette containing the
g85B–ESAT6 fusion under the control of the lacZ promoter,
lasmid pMCT6 was obtained from the Statens Serum Insti-
ute, Denmark [29,36]. PCR fragments generated from this fusion
ere initially ligated into pGEM-Teasy (Invitrogen) for easier
anipulation. Plasmid p2795, required for integration of the
xpression cassette into the phoN gene of the SL3261 genome,
as a kind gift of Michael Hensel [37]. The red recombi-
ase plasmid, pKD46 was utilised for homologous recombination
f the expression cassette into the phoN region of SL3261
hromosome [38]. Primers were designed using MacVector soft-
are and are shown in Table 1. When required, kanamycin
Invitrogen) was used at 50g/mL and ampicillin (Roche) at
00g/mL.AGACGATAATGCCAGGGCA
GAATCGGGGAAACCAAAG
TATTCTACGCGAACTCGGCG
2.2. Construction of recombinant Salmonella SL3261mycolacZ
The red recombinase technique devised by Datsenko and Wan-
ner was utilised for integration of the expression cassette into the
phoN gene of the SL3261 genome [38]. This required the use of
plasmid p2795 which was speciﬁcally designed by Husseiny and
Hensel for integration of expression cassettes into the genomes of
bacteria using the red recombinase system [37]. This vector per-
mitted mobilisation of the Ag85B–ESAT6 fusion expressed under
the lacZ promoter into the phoN site of S. Typhimurium SL3261.
The construction of the integrated cassette is illustrated in Fig. 1
and is brieﬂy described below. We cloned the expression cassette
into the multiple cloning site (MCS) of p2795, which contains the
kanamycin resistance gene for selection purposes, using enzymes
BamHIandSalI (Fig. 1A).UsingprimersphoNhensFandphoNhensR,
we ampliﬁed the entire region including phoN sequences at each
end, the kanamycin gene and lacZ-Ag85B–ESAT6 cassette (Table 1
and Fig. 1B). The resulting PCR product was treated with DpnI to
remove any plasmid DNA template.
For integration into the phoN region of SL3261 chromosome,
the PCR product was electroporated into SL3261 harbouring the
red recombinase plasmid, pKD46 (Fig. 1C). 2g of PCR prod-
uct was used for this procedure. Kanamycin resistant colonies
were selected and were further plated at 37 ◦C so as to encour-
age loss of the pKD46 plasmid. The chromosome bearing the
Ag85B–ESAT6 expression cassette was then mobilised into a new
S. Typhimurium SL3261 derivative via transduction using the bac-
teriophage P22 [39]. Remaining kanamycin resistant colonies were
retained andWestern blots performed to conﬁrm expression of the
Ag85B–ESATB fusion proteins via the lacZ constitutive promoter.
Primers phoNseqF, phoNseqR and mycoseqR were used to conﬁrm
sequence. One isolate was named SL3261mycolacZ and was used
in all further immunisation experiments (Table 1 and Fig. 1D).
2.3. Analysis of Ag85B–ESAT6 expression
In order to determine expression levels of Ag85B–ESAT6 from
SL3261mycolacZ, LB-broth cultures were harvested by centrifuga-
tion and resuspended in phosphate-buffered saline (PBS) (pH 7.4)
to an optical density at 600nm (OD600) of 1. The suspension was
then mixed with an equal volume of 2× sodium dodecyl sulphate
(SDS) loading buffer and separated by SDS-polyacrylamide gel
(SDS-PAGE) electrophoresis using a 4–20%-gradient gel (Bio-Rad).
Proteins were transferred to polyvinylidene ﬂuoride membranes
(Immobilon-P) by Western transfer and detected with monoclonal
anti-Ag85B antibody (1:50) obtained from the Statens Serum Insti-
tute, Denmark.
2.4. Vaccination of mice with serovar TyphimuriumFor inoculation of mice, the serotype Typhimurium strain
was grown statically overnight in LB-broth supplemented with
kanamycin as appropriate. Bacteria were harvested by centrifuga-
tion, washed, and then suspended in PBS (pH 7.4) to approximately
5×109 CFUmL−1. Serial dilutions of the bacterial culture were also
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Fig. 1. Schematic diagram for the construction of targeting construct and chromosomal integration of expression cassette. (A) Expression cassette consists of a constitutive
promoter (lacZ), a gene fragment encoding the model vaccine fusion antigen Ag85B–ESAT6 (grey symbol). Expression cassette for expression of Ag85B–ESAT6 was inserted
into the multiple cloning site of p2795 within SalI (black line) and BamH1 (grey line) sites. p2795 contains the kanamycin resistance gene (diagonal lines) and binding
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potted onto LB agar plates and cultured at 37 ◦C overnight to con-
rm concentration. Groups of 6–8-week-old female C57BL/6 mice
obtained from Harlan Ltd., UK, Bicester) were inoculated orally
y gavage with 200L of bacterial suspension each. On days 21,
0, 57 and 120 blood was collected and sera prepared by standard
echniques and stored at −20 ◦C for further analysis. In addition,
n days 50, 57 and 120, groups of 5 animals were euthanized to
arvest splenocytes and lung and nasal lavages performed.
.5. Vaccination of mice using the prime-boost regimen
Mice were primed orally with SL316mycolacZ on day 0 and
ntranasally (i.n.) boosted on day 50with either PBS or 20g LTK63
negative controls) or 20g LTK63 plus 25g Ag85B–ESAT6 in
volume of 15–20L/nostril. As a positive control, one group of
ice were i.n. immunised with 1g LT and 25g Ag85B–ESAT6 on
ay 0 as this has previously been shown to induce both antibody
nd cytokine responses (unpublished observations). The adjuvants
T and LTK63 were a kind gift from Novartis, Italy, and puriﬁed
g85B–ESAT6was obtained from the Statens Serum Institute, Den-
ark. Proteins were mixed immediately before use. Blood samples
ere obtained on day 57 and day 120. Groups of 5 animals were
uthanized at the same time-points to harvest splenocytes and
erform lung and nasal lavages.
.6. Evaluation of antibody responses
Serum samples from mice post-immunisation were analysed
or the presence of total Ig, IgG, IgG1, IgG2a or IgA. Brieﬂy, ELISA
lates (Nunc Maxisorp) were coated overnight at 4 ◦C with 50L of
2g/mLsolutionofpuriﬁedAg85B–ESAT6 incoatingbuffer (0.1M
a2HPO4 at a pH of 9) and then blocked with 3.0% BSA at room
emperature for 1h. Serum samples were diluted in 0.1% BSA start-
ng at 1:100. Each plate contained control wells with preimmuneette and resistance gene was ampliﬁed by knock-in primers containing sequences
L3261 harbouring pKD46 for expression of Red recombinase was transformed with
osomal target gene, phoN (white symbol) by the targeting construct were selected.
sera, PBS (pH 7.4), or a known positive immune serum and incu-
bated for 1h at 37 ◦C. Antibodies conjugated to HRP were diluted
1:1000 and plates incubated for a further 30min at 37 ◦C. The level
of HRP associatedwith eachwell was then determined using Sigma
Fast o-phenylenediamine dihydrochloride (50L per well) colori-
metric substrate. The reaction was stopped after 15min by the
addition of 2.5M H2SO4. The OD490 was determined, and the titre
was expressed as the reciprocal of the dilution giving an OD of 0.3.
Lung and nasal lavages, performed post-mortem, were used
to measure mucosal antibody responses. Lavages were performed
using 1mL of ice-cold PBS containing a cocktail of protease
inhibitors (Roche), which was ﬂushed in and out of the lungs and
nasal passages with a ﬁne-tipped Pasteur pipette inserted via the
trachea. Lavage ﬂuids were then stored at −20 ◦C prior to analy-
sis utilising the above ELISA protocol modiﬁed as follows. Lavage
ﬂuid was diluted in 0.1% BSA starting at 1:10. A rat monoclonal
anti-mouse IgA, conjugated to biotin (BD Biosciences), was used as
the secondary antibody at 1:1000. To detect the biotin-conjugated
antibody, plates were washed four times in PBS-T and then 50L
of streptavidin-HRP diluted at 1:1000 in PBS-T was added to each
well. Plates were developed and titres measured as described
above.
2.7. Cytometric bead array cytokine analysis
Mice were sacriﬁced and their spleens removed and seeded, in
duplicate at a concentration of 5×105 cells/well. Splenocytes were
stimulated with either Ag85B–ESAT6 or Con A (both at 5g/mL)
or RPMI medium. Plates were incubated at 37 ◦C and 5% CO2
for 36–48h. Cytokines IL-2, IL-4, IL-5, IL-6 and IFN- were anal-
ysed using cytometric bead analysis ﬂexi-kits (BD Biosciences)
and assays were performed per the manufacturer’s instructions.
Samples were then analysed on a FACSAria ﬂow cytometer (BD
Biosciences). The limit of detection was ∼8pg/mL for all cytokines.
ine 27 (2009) 6894–6904 6897
2
g
l
e
5
d
o
e
s
w
t
c
a
v
H
[
d
f
o
T
a
a
c
3
d
p
m
b
a
r
c
a
t
Fig. 2. Ag85B–ESAT6 expression by recombinant S. Typhimurium vaccine strain.
Bacterial lysates, were separated by SDS-PAGE electrophoresis (4–20% gradient gel;
2×107 bacteria per lane), blotted onto nitrocellulose, and probed with a mono-
clonal antibody against native Ag85B. Lanes 1 and 2 shows log phase static cultures
of SL3261mycolacZ and the SL3261 parental strain, respectively. The protein was
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.8. Guinea pig challenge study
Protection was evaluated in outbred female Dunkin–Hartley
uinea pigs (weighing between 250 and 300g), obtained from Har-
an Ltd., UK, Bicester. Vaccine efﬁcacy was evaluated in groups of
ight guinea pigs in comparison to positive controls that received
×104 CFU of BCG Danish strain 1331 and PBS negative controls
elivered subcutaneously (s.c.). SL3261mycolacZ was delivered
rally in 1mL of suspension (total dose of 5.5×108 CFU) and deliv-
red at the back of the mouth slowly to ensure the full dose was
wallowed. Four weeks later, one group of animals was boosted
ith 20g Ag85B–ESAT6 plus 50g of LTK63 delivered s.c. in a
otal volume of 250L.
Animalswere rested for 10weeks post-vaccination before being
hallengedwith anaerosol dose ofM. tuberculosis. Guineapigswere
erosol challenged using a contained Henderson apparatus as pre-
iously described [40,41]. Fine particle aerosols of M. tuberculosis
37Rv, with a mean diameter of 2m (diameter range, 0.5–7m)
42], were generated using a 3-jet collision nebuliser and delivered
irectly to the snout of each animal. The aerosol was generated
rom a water suspension containing 5×106 CFUmL−1 in order to
btain an estimated retained, inhaled dose of 20–50CFU/lung [41].
he intention was to infect the animals with a relatively low dose
erosol challenge since this iswithin the rangeof doses convention-
lly used in guinea pig models of tuberculosis. Following aerosol
hallenge, the guinea pigs were housed at ACDP containment level
and monitored regularly for weight changes as an indicator of
isease. The animals were culled humanely at study end (30 weeks
ost-challenge) or at the humane end-point deﬁned as 20% loss of
aximal body weight with peritoneal overdoses of sodium pento-
arbitone.
When a guinea pig was euthanized, the spleen and lungs were
◦septically removed and stored at −20 C until processed for bacte-
iology. Frozen tissues were thawed and homogenised and viable
ounts were performed on Middlebrook 7H11+OADC selective
gar. Plates were incubated at 37 ◦C for 4 weeks before counting
he number of M. tuberculosis CFU. Vaccine efﬁcacy was assessed in
ig. 3. Serum Ig anti-Ag85B–ESAT6 antibody response in C57BL/6mice following oral Salm
×109 CFU of SL3261mycolacZ on day 0 and then boosted with 25g Ag85B–ESAT6+20
mmunised with wild-type SL3261 or PBS, and then also boosted on day 50 with suitable
ice were left for 21, 50, 57 and 120 days and then sample bled to determine anti-Ag85B–
otal antibody titres using a cut off of OD 0.3 on days 50 (prior to boost) and 57 (plus boost
he signiﬁcant values of *p<0.05; **p<0.01 and ***p<0.001 as determined using the Krus
ontrols.identiﬁed by comparison to 1g of puriﬁed recombinant Ag85B–ESAT6 standard
(Lane 3). The protein band corresponding to Ag85B–ESAT6 is indicated by the arrow.
The * indicates dimers of Ag85B–ESAT6 in the puriﬁed protein.
termsof reduction inbacterial counts in lungand spleen.Guineapig
experimental workwas conducted according to UK laws for animal
experimentation and was approved by a local ethical committee at
the Health Protection Agency, CEPR, Porton Down, UK.
2.9. Statistical analysis of data
Experimental results were plotted and analysed for statistical
signiﬁcance utilising Prism4 software (GraphPad Software Inc.).
3. Results3.1. Construction of recombinant Salmonella vaccine and in vitro
expression of antigen Ag85B–ESAT6
Several genetic approaches have been developed that facil-
itate the chromosomal expression of heterologous antigens in
onellaprime and i.n. protein boost.Micewere orally vaccinatedwith approximately
g LTK63 or appropriate antigen controls on day 50. Negative control mice were
antigens. Positive controls received 1g LT plus 10g Ag85B–ESAT6 i.n. at day 0.
ESAT6-speciﬁc Ig antibodies, which were determined by ELISA. (A) Graphs express
) and on (B) day 120. The black bar shows the geometric mean from the group with
kal–Wallis test followed by Dunn’s Multiple Comparison test compared to negative
6898 L.J. Hall et al. / Vaccine 27 (2009) 6894–6904
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oig. 4. Ag85B–ESAT6-speciﬁc IgG1:IgG2a antibody titre ratios. C57BL/6 mice wer
mmunised had no detectable IgG subtype titres (data not shown). Titres shown
mmunisation. Bars represent geometric means. Statistical signiﬁcance was deter
*p<0.05 and **p<0.01).
almonella and one such system, based upon phoN as an integra-
ion site, was selected for this study [37]. This approach relies
n the exploitation of a single copy of the heterologous gene
o drive immunologically relevant levels of antigen expression.
hromosomal integration has the advantage of providing a sta-
le platform for antigen expression, favouring the subsequent
xploitation of the technology in applied clinical studies. Here,
he Escherichia coli promoter lacZ was chosen to drive constitutive
xpression of the Ag85B–ESAT6 protein. Previously, both the ssaG
romoter from Salmonella pathogenicity island-2 (SPI-2) and the
ig. 5. Systemic and mucosal IgA induced by immunisation with Salmonella live vector
L3261mycolacZ vaccine candidate and i.n. boosting with antigen plus adjuvant. (A) Grap
o boost) and then on days 57 (plus boost). (B) Lung and nasal wash IgA titres are also sho
r PBS served as negative controls. For group and statistics details see legend of Fig. 3.unised as described in Fig. 3 legend. Negative control mice, i.e. PBS and SL3261
determined in individual serum samples obtained on days 50, 57 and 120 after
by using the Kruskal–Wallis test followed by Dunn’s Multiple Comparison test
nirB promoter from E. coli were used to drive in vivo expression
of Ag85B–ESAT6 from plasmids. However, using multi-copy plas-
mids and three doses of the recombinant Salmonella strains, we
found that antigen expression and subsequent immune responses
generated in immunised mice were signiﬁcantly lower than those
seen using a single dose of Salmonella harbouring the chromoso-
mal driven antigen expression from the constitutive lacZ promoter
(Hall et al., unpublished). This is similar to what was reported
by Husseiny et al. when they compared chromosomal integration
of an in vivo inducible (sseA from SPI-2) and a constitutive pro-
vaccine. Antibody titres were measured following oral prime immunisation with
h shows titres obtained from individual serum samples collected on days 50 (prior
wn. Serum and washes isolated from mice immunised with SL3261 parental strain
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oter to drive antigen expression in a Salmonella vaccine vector
37].
The red recombinase approach was utilised for integration of
he expression cassettes into the chromosome of S. Typhimurium
L3261 (Fig. 1). Whole-cell lysates of SL3261mycolacZ, or of the
arental control strain, were grown statically at 37 ◦C to allow
g85B–ESAT6 expression and these were then probed with a mon-
clonal antibody against Ag85B. A positive control of puriﬁed
g85B–ESAT6 protein was also probed. The Western blots anal-
sis identiﬁed two major immuno-reactive polypeptides in both
L3261mycolacZ lysates and with puriﬁed Ag85B–ESAT6 protein.
hese were absent in similar SL3261 lysates. The electrophoretic
obility of these bands corresponded to that expected for the
g85B–ESAT6 fusion protein, 37kDa and the single Ag85B pro-
ein from breakdown of the fusion protein at 31kDa (Fig. 2).
o test stability in vivo, mice were orally immunised with the
L3261mycolacZ strain as described in Section 2. Plating on
elective agar with or without kanamycin at 7 days following
hallenge indicated that the S. Typhimurium construct was sta-
le.
.2. Humoral immunogenicity of recombinant Salmonella
accine in an oral priming i.n. protein boost regimen
.2.1. Total Ig serum anti-Ag85B–ESAT6 response
In order to determine if SL3261mycolacZ was effective in stim-
lating humoral immune responses, sera collected from mice
t various time-points after oral immunisation were tested to
scertain the kinetics of anti-Ag85B–ESAT6 Ig antibody responses
y ELISA. C57BL/6 mice were orally immunised with either,
L3261mycolacZ, SL3261 or PBS as described in Section 2. Mice
ere then boosted i.n. with PBS, LTK63 or LTK63 and Ag85B–ESAT6
t day 50. The antibody response that followed a single immu-
isation with SL3261mycolacZ administered orally was found to
e signiﬁcant (p<0.001), 21 days post-priming, when compared
o PBS and SL3261 vaccinated mice (data not shown). These anti-
g85B–ESAT6 titres were observed to increase over 10-fold by day
0, where 100% of the mice showed signiﬁcant (p<0.001) titres
Fig. 3A). Indeed, 6 months (day 120) after initial immunisation
ith SL3261mycolacZ, mice were still observed to have signiﬁ-
antly robust (p<0.05) Ig titres (Fig. 3B). Boosting i.n. with LTK63
nd Ag85B–ESAT6 in SL3261mycolacZ-primed mice appeared to
nhance serum Ig anti-Ag85B–ESAT6 responses at both 7 days and
0 days post-boost (Fig. 3A and B, respectively). Mice vaccinated
ith SL3261mycolacZ, and then boosted with either PBS or LTK63,
id not show any increase in Ag85B–ESAT6-speciﬁc titres 7 days
fter boosting (Fig. 3A). As expected, mice primed with SL3261
ith/without a boost of either PBS or LTK63 did not have any sig-
iﬁcant (p>0.05) anti-Ag85B–ESAT6 titres (Fig. 3A). Mice orally
rimed with SL3261 and i.n. boosted with puriﬁed Ag85B–ESAT6
nd LTK63 did have modest anti-Ag85B–ESAT6 titres 7 days after
oosting, however only 60%of the animals sero-converted (Fig. 3A).
s expected, thepositive control group, i.e. thoseanimals i.n. immu-
ised with LT and Ag85B–ESAT6, attained high titres throughout
he study (Fig. 3).
.2.2. IgG sub-class responses
Sera collected on days 50, 57 and 120 from primed and/or
oosted mice were further analysed to ascertain Ag85B–ESAT6-
peciﬁc IgG1:IgG2a sub-class ratios as an indirect assessment of the
-helper cell response bias (Fig. 4). On all days, mice primed with
L3261mycolacZ with/without LTK63 or Ag85B–ESAT6 plus LTK63
oost were found to be more IgG2a-biased, as depicted by the low
gG1:IgG2a ratios. However, there were no IgG1:IgG2a proﬁles that
ere statistically different between these experimental groups.
ice vaccinated with the SL3261 parental strain and then boosted (2009) 6894–6904 6899
with adjuvant and Ag85B–ESAT6 had an IgG1 biased response;
however, it was not statistically different from those animals
immunised with the recombinant vaccine strain, SL3261mycolacZ,
plus or minus a boost. Importantly, mice dosed once with the
adjuvant LT and Ag85B–ESAT6 engendered a signiﬁcantly greater
(p<0.05) proportion of IgG1-speciﬁc anti-Ag85B–ESAT6 antibod-
ies than those primed with SL3261mycolacZ and consequently
boosted over all time-points tested.
3.2.3. Serum and mucosal IgA response
The systemic and mucosal IgA response following admin-
istration of the SL3261mycolacZ inoculum was also analysed.
The levels of anti-Ag85B–ESAT6 IgA in the serum of immu-
nised mice is shown in Fig. 5A. The anti-Ag85B–ESAT6 IgA
titres were signiﬁcantly higher (p<0.001) in mice primed with
SL3261mycolacZ with or without boosting when compared to neg-
ative control animals, i.e. those immunised with PBS or SL3261.
However, only 80% of the mice that received SL3261mycolacZ
plus an LTK63 boost sero-converted and were found not to be
signiﬁcantly different from the negative control mice. The anti-
Ag85B–ESAT6 IgA response in those mice i.n. immunised with LT
and Ag85B–ESAT6 was 100-fold lower than that elicited by the
other groups immunised with the candidate vaccine and only 40%
of animals sero-converted. At the ﬁnal time-point (day 120), the
titres of anti-Ag85B–ESAT6 IgA induced by immunisation with
SL3261mycolacZ returned to levels similar to the negative control
mice (i.e. undetectable). Notably, only onemouse orally immunised
with SL3261mycolacZ and i.n. boosted with Ag85B–ESAT6 antigen
and LTK63 still had detectable IgA levels at this time-point (data
not shown).
Since vaccination through the oral and nasal route has the
potential to induce mucosal protective responses, we investigated
the induction of IgA in nasal and lung washes of mice immunised
with SL3261mycolacZ vaccine. We also compared the levels of
mucosal IgA after the i.n. boost. Mucosal Ag85B–ESAT6-speciﬁc
IgA titres were demonstrated in both nasal and lung washes fol-
lowing immunisation with SL3261mycolacZ; signiﬁcant responses
(p<0.01) were readily detected 50 days after the ﬁrst dose and
were still present 7 days after boosting (day 57) (Fig. 5B). However,
mucosal IgA couldnot bedetected in anygroups after completionof
the experiment at day 120 (data not shown). A slightly higher titre
of IgAwasobserved in lung andnasalwashes frommice immunised
with SL3261mycolacZ and boosted i.n. with Ag85B–ESAT6 antigen
plus LTK63 adjuvant than in mucosal washes from those receiving
SL3261mycolacZ with or without the negative control boosts. IgA
antibodies were undetectable in mice immunised with SL3261 or
PBS (negative controls) including those mice receiving SL3261 plus
the LTK63 and Ag85B–ESAT6 boost.
3.3. Evaluation of cytokine responses after recombinant
Salmonella vaccination
To analyse the TH type of immune response induced in the
different groups of immunised mice, we evaluated the cytokines
secreted in cell culture supernatants derived from splenocytes
after in vitro restimulation with puriﬁed Ag85B–ESAT6 protein.
CBA was used to determine the secreted levels of the cytokines:
IFN-, IL-4, IL-6, IL-2 and IL-5. Fig. 6A illustrates the mean con-
centrations (pg/mL) of the various cytokines secreted from spleen
cells for each group on day 50 (prior to boost) and day 57 (post-
boost). We observed signiﬁcant levels (p<0.05) of all cytokines
in those mice immunised with SL3261mycolacZ alone as well as
those mice also receiving i.n. boosts (either LTK63 or LTK63 plus
Ag85B–ESAT6), with the exception of IL-5 levels which were not
signiﬁcantly different (p>0.05) in SL3261mycolacZ-primed and
adjuvant and Ag85B–ESAT6 boosted animals, when compared to
6900 L.J. Hall et al. / Vaccine 27 (2009) 6894–6904
Fig. 6. Ag85B–ESAT6-speciﬁc cytokine responses in C57BL/6 mice primed with Salmonella live vector vaccine and boosted with LTK63 and Ag85B–ESAT6. Ag85B–ESAT6-
speciﬁc cytokine secretion of splenocytes from mice primed by oral immunisation with SL3261mycolacZ, SL3261, or PBS (day 0) and boosted by i.n. administration
of Ag85B–ESAT6 plus LTK63 or appropriate controls (day 50) are shown. Spleens were harvested on days 50 and 57, and 120. (A) Figure shows cytokine levels
from stimulated splenocytes on days 50 and 57. Cytokine responses were measured upon in vitro stimulation with Ag85B–ESAT6 for 36–42h including IFN-, IL-4, IL-2,
IL-5 and, IL-6. (B) IFN- levels fromsplenocytes isolated onday120 are also shown. Cellswere also stimulatedwithConA (positive control) andRPMI+ media (negative control).
L.J. Hall et al. / Vaccine 27 (2009) 6894–6904 6901
Fig. 7. Protective responses in vaccinated animals. (A) Survival curve of guinea pigs thatwere aerosol-infectedwithM. tuberculosisH37Rv throughout an observation period of
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eduction in bacterial numbers compared to PBS controls is indicated (*p<0.05; *
ultiple Comparison test.
egative controls. Indeed, levels of IFN-, IL-2 and IL-6 in animals
oosted with adjuvant and Ag85B–ESAT6 was signiﬁcantly higher
hen compared to those just immunised with SL3261mycolacZ
lone (p<0.01compared top<0.05) (Fig. 6A).Mice immunisedwith
L3261 parental strain plus or minus a boost with LTK63 did not
ave signiﬁcant levels (p>0.05) of any tested cytokines on days
0 and 57 (Fig. 6A). However, mice immunised with SL3261 and
oosted with LTK63 and Ag85B–ESAT6 were found to have sig-
iﬁcant levels (p<0.001) of IL-4, IL-5 and IL-6, but importantly
ot (p>0.05) IFN- (Fig. 6A). IFN- and IL-5 levels signiﬁcantly
p<0.05) persisted throughout the experimental period up until
ay 120, in those mice vaccinated with SL3261mycolacZ alone
hen compared to SL3261 immunised mice (Fig. 6B and data not
hown).Moreover, in thosemice primedwith SL3261mycolacZ and
oosted with LTK63 and Ag85B–ESAT6 we observed signiﬁcantly
igher levels (p<0.05) of all cytokines tested at this late time-point
Fig. 6B and data not shown). The positive control group (i.e. those
mmunised with LT and Ag85B–ESAT6 were found to have modest
evels of all cytokines tested at all time-points (Fig. 6 and data not
hown).
olumns represent the mean (±SD) stimulation indices of splenocytes from 5 to 10 anim
.n.-boosted mice, compared to negative control mice, is indicated (*p<0.05; **p<0.01; ***
omparison test. None of the cytokines tested were detected in splenocyte populations
mmunised mice upon stimulation with ConA (data not shown).differences in survival were calculated by the log-rank test ***p≤0.001. Inﬂuence
inea pigs infected by the aerosol route. Columns represent log10 CFU (±SD). The
01; ***p<0.001) as determined using the Kruskal–Wallis test followed by Dunn’s
3.4. Protective efﬁcacy of prime-boost regimen
Challenge experiments were performed using the discrimina-
tive aerosol-infection guinea pig model to evaluate whether the
strong immune responses induced in mice would confer protec-
tion against M. tuberculosis challenge. Ten weeks post-vaccination,
guinea pigs were challenged with a low dose aerosol of M. tuber-
culosis and survival was monitored over the following 30 weeks.
The experiment was terminated 30 weeks post-challenge when
100% of animals in the PBS group had reached the humane weight
loss end-point (Fig. 7A). The BCG Danish s.c. group survived sig-
niﬁcantly longer when compared to the PBS group (p≤0.001).
Both SL3261mycolacZ immunised animals with and without an
Ag85B–ESAT6 in LTK63 boost displayed greater survival compared
to the saline group but this difference did not reach statistical
signiﬁcance relative to PBS (log-rank test p=0.070 [30% sur-
vivors] and 0.078 [50% survivors], respectively). However, boosting
SL3261mycolacZvaccinatedanimalswithAg85B–ESAT6andLTK63
was shown to improve efﬁcacy in terms of survival to a level
that was statistically equivalent to the BCG Danish (1331) vac-
als per group. The increase in cytokine levels between SL3261mycolacZ-primed,
p<0.001) as determined using the Kruskal–Wallis test followed by Dunn’s Multiple
stimulated with medium alone. All cytokines were detected in splenocytes from
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ine unlike the group that was not boosted (log-rank test p=0.009
nd 0.085, respectively). Fig. 7B shows the concentration of M.
uberculosis in the organs from each group either when the ani-
als had reached their humane end-point during the study or at
he termination of the experiment at 30 weeks post-challenge.
he BCG Danish (1331) s.c. group showed signiﬁcantly reduced
acterial load (p<0.01) in the lung and spleen compared to the
quivalent tissues in the PBS negative control group. Orally deliv-
red SL3261mycolacZ immunised animals showed no signiﬁcant
eduction (p>0.05) in bacterial load in either the lungs or spleen
ompared to the PBS group. However, boosting SL3261mycolacZ
accinated animals with Ag85B–ESAT6 and LTK63 was shown to
ot only reduce bacterial load signiﬁcantly (p<0.05) in both lungs
nd spleen when compared to the PBS control group but this
rotection, in terms of reduced bacterial load, was statistically
quivalent (p>0.05) to the BCG Danish (1331) s.c. positive control
roup.
. Discussion
As a delivery system, live attenuated Salmonella vaccines are
apable of eliciting an immune response to guest antigens from
acteria, parasites and viruses [10,13,43]. As bacterial vectors, both
. Typhi and S. Typhimurium have been extensively studied in
oth animal models and humans [44,45]. In addition, immunisa-
ion at one mucosal inductive site (e.g., intestinal) can lead to an
mmune response at another, anatomically remote, mucosal effec-
or site (e.g., lungs) due to the sub-networks that exist within
he mucosal immune system [46–49]. We reasoned, therefore,
hat a Salmonella-based live vector vaccine could be an excellent
andidate to prime immune responses by delivering the foreign
usion antigen, Ag85B–ESAT6, directly into antigen presenting cells
APC), while providing a strong TH1 cytokine milieu and other
mmunomodulatory signals that are important for clearance and
rotection against tuberculosis.
Several studies have indicated that both oral and intravenous
dministration of recombinant Salmonella strains may be efﬁcient
outes of immunisation for a vaccine against tuberculosis. Previ-
usly, Hess and colleagues used S. Typhimurium to express and
ecrete theM. tuberculosisproteinAg85B. They transformedSL7027
ith a plasmid encoding the HlyB/HlyD/TolC export machinery
from E. coli) and the ag85b gene. Thosemice orally vaccinatedwith
he recombinant Salmonella strain were offered partial protection
fter intravenous (i.v.) challenge with M. tuberculosis [50]. A fur-
her study also used S. Typhimurium as a vector to export another
. tuberculosis antigen, ESAT6, via the haemolysin (HlyA) secre-
ion system. Mice immunised intravenously with this Salmonella
accine expressing ESAT6 were found to have reduced num-
ers of tubercle bacilli in the lungs throughout the course of M.
uberculosis infection [51]. However, plasmid-based systems have
nherent problems with stability, and antibiotic resistance genes
re discouraged for incorporation into live vectors for approval for
icensed clinical use [52]. Chromosomal-dependent delivery sys-
ems do have promise as they confer stability and do not require
selectable marker for maintenance. In fact, phase I human trails
sing the S. typhi vaccine candidate ZH9 expressing LT-B antigen
rom the chromosome were found to be safe and immunogenic,
gain highlighting the advantages of utilising this approach [13].
ere, we cloned the tuberculosis fusion antigen Ag85B–ESAT6 into
he chromosomal phoN gene of SL3261. The ag85B–esat6 gene is
nder the constitutive control of the lacZ promoter with strong
g85B–ESAT6 production readily detectable under in vitro growth
onditions. Therefore this expression system would hopefully be
more realistic basis for an efﬁcient Salmonella delivery system
f Ag85B–ESAT6 for use in humans based upon a S. Typhi con-
truct. (2009) 6894–6904
Prime-boost techniques, involving heterologous vaccination
regimens have shown promise for inducing both cellular and
humoral immune responses [53,54]. Some recent studies have
examined the administration of Ag85B–ESAT6 i.n. in conjunction
with a number of different mucosal adjuvants. One such study
examined the immunogenicity of Ag85B–ESAT6 in combination
with the adjuvant LTK63. Here, three immunisation doses given at
two weekly intervals-induced strong IFN- responses from T cells
as well as providing signiﬁcant reduction in M. tuberculosis CFUs in
both the lungs and the spleen, comparable to that seen in the BCG
controls [4].With this research inmindwe also decided to incorpo-
rate our live attenuated Salmonella vaccine, SL3261mycolacZ, into
an oral priming, i.n. boosting vaccination regimen using puriﬁed
Ag85B–ESAT6 and the adjuvant LTK63.
We observed high titres of anti-Ag85B–ESAT6 Ig in the serum of
mice primed orally with SL3261mycolacZ and in animals primed
and i.n. boosted with puriﬁed Ag85B–ESAT6 and the adjuvant
LTK63, with prominence of the IgG2a subtype. The differential pro-
duction of cytokines has important effects on the Ig isotype, and the
high ratio of IgG2a to IgG1 antibodies speciﬁc for Ag85B–ESAT6 is
consistent with a heightened TH1 response, since IFN- is required
to stimulate IgG2a secretion and is associated with inhibition of
IgG1 production [55]. Indeed, the immunisation using attenuated
recombinant Salmonella has already been reported as inducing a
TH1-type response preferentially [11,56]. Mice primed and then
boosted with or without Ag85B–ESAT6 plus LTK63 also exhib-
ited signiﬁcantly high IgA titres in both serum and lung and nasal
washes.
As shown in Fig. 6, priming mice with SL3261mycolacZ was suf-
ﬁcient to induce signiﬁcant and long-lasting levels of all cytokines
tested, i.e. IL-4, IL-2, IL-5, IL-6 and IFN-. For a number of cytokines,
their production was further elevated after i.n. boosting with
Ag85B–ESAT6 and LTK63 (i.e. IL-6, IL-2 and IFN-). Notably, the
T cell response was dominated by IFN-, the importance of which
for the protection againstM. tuberculosis has been shown in several
studies [57,58]. IFN- contributes to protective immunity against
M. tuberculosis by activatingmacrophages tomore effectively elim-
inate this pathogen [59,60]. Individuals defective in genes for IFN-
and IFN- receptors are prone to serious M. tuberculosis infec-
tions [61]. Interestingly, those animals primed with the parental
SL3261 strain, and boosted with puriﬁed protein and adjuvant,
exhibited strong production of the TH2-associated cytokines IL-
4 and IL-5, however we only observed a minor TH2 response in
SL3261mycolacZ immunised animals. A number of studies have
shown that these cytokines, if produced in excess, may result in
failure to control infection resulting in widely disseminated tuber-
culosis [62]. The differences in cytokine proﬁles between mice
primed with the vaccine strain compared to those immunised with
the negative control strain after boosting indicates the signiﬁcant
TH1 environment the recombinant SL3261mycolacZ strain induces
after administration. In comparison to the recombinant Salmonella
vaccine candidate expressing Ag85B (S. Typhimurium p30), con-
structed by Hess and colleagues, we observed that only one oral
dose of SL3261mycolacZ was enough to induce approximately four
times more IFN- than three oral doses of S. Typhimurium p30.
Recent studies in mice [63,64] and humans [65,66] have iden-
tiﬁed potentially dangerous side-effects of administering antigen
and adjuvant i.n. Therefore, the guinea pig studies described here
include mucosal priming with Salmonella vaccine strain and s.c.
boosting with Ag85B–ESAT6 and LTK63. After aerosol challenge
with pathogenic M. tuberculosis, guinea pigs immunised with
SL3261mycolacZ alone did not have signiﬁcantly improved protec-
tion when compared to PBS controls. Only those animals primed
with the Salmonella vaccine candidate and s.c. boosted with LTK63
and Ag85B–ESAT6 were found to have statistically equivalent pro-
tection to those animals immunisedwith BCG.Whereas, themouse
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odel has been extensively used to determine efﬁcacy of possi-
le human S. Typhi vaccine candidates, very few studies have used
uinea pigs. Several studies suggest that the intracellular envi-
onment of macrophages of guinea pigs may be unfavourable for
he proliferation of S. Typhimurium [67–73]. Rapid destruction
f the vaccine vector by guinea pig macrophages and conse-
uently reduced levels of Ag85B–ESAT6 may therefore impact on
he strength of the immune response and may explain why we
nly observed a modest increase in protection in those animals
accinated with SL3261mycolacZ alone. Even though the immune
esponses induced by oral vaccination alone did not confer sig-
iﬁcant protection, when these animals were boosted with LTK63
nd Ag85B–ESAT6 we did observe signiﬁcantly lower M. tubercu-
osis CFU in both the lungs and spleens of these immunised mice
nd a protective effect which was similar to BCG vaccinated con-
rols. These data are encouraging for using SL3261mycolacZ, or the
. Typhi vector equivalent, in humans as part of a heterologous
rime-boost strategy. Although, the antibiotic resistance marker
resent in SL3261mycolacZwouldhave tobe removedbefore itwas
n acceptable construct to be used in human vaccination. Indeed,
s BCG has been used for over six decades, and over three billion
oses have been administered, further studies could also investi-
ate the use of this novel Salmonella vaccine as a boost to enhance
nd prolong the protective immunity of BCG prime immunisation.
In conclusion, we have demonstrated for the ﬁrst time that
ice vaccinated with attenuated S. Typhimurium expressing the
g85B–ESAT6 protein via the chromosome (SL3261mycolacZ)
eveloped potent humoral and cellular immune responses. When
hese primed mice were consequently i.n. boosted with the adju-
ant LTK63 and Ag85B–ESAT6, we observed a further signiﬁcant
ncrease in both antibody titres and cytokine levels. Finally, when
ested for protective efﬁcacy in the aerosol guinea pigmodel, prim-
ng with SL3261mycolacZ and boosting with antigen and adjuvant
igniﬁcantly improved protection in animals thatwas equivalent to
evels observed inBCGvaccinated controls. Thedatapresentedhere
rovide a foundation for future studies involving an orally admin-
stered recombinant S. Typhi live vector vaccine stably expressing
he M. tuberculosis fusion antigen, Ag85B–ESAT6, as part of an oral
riming, boosting vaccination regimen.
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